Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome

Digestive Diseases and Sciences

Volumn 52, Issue 3, 2007, Pages 742-748

  Esrailian, Eric ^a,b   Pantangco, Eugene R ^b   Kyulo, Namgyal L ^c   Hu, Ke Qin ^c   Runyon, Bruce A ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; Portal hypertension; Renal failure

Indexed keywords

CREATININE; MIDODRINE; OCTREOTIDE; PENTOXIFYLLINE;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HEPATORENAL SYNDROME; HUMANS; MALE; MIDDLE AGED; MIDODRINE; MULTIVARIATE ANALYSIS; OCTREOTIDE; SURVIVAL ANALYSIS; VASOCONSTRICTOR AGENTS;

EID: 33847179154     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9312-0     Document Type: Article

References (24)

1. v. Frerichs T (1877) Tratado práctico de las enfermedades del hígado, de los vasos hepáticos y de las vias biliares. Librería Extranjera y Nacional, científica y Literaria, Madrid, pp 362-353
2. Flint A (1863) Clinical report on hydro-peritoneum based on an analysis of forty-six cases. Am J Med Sci 45:306-339
3. Hecker R, Sherlock S (1956) Electrolyte and circulatory changes in terminal liver failure. Lancet 2:1221-1225 4.
4. Arroyo V, Ginés P, Gerbes A, Dudley FJ, Gentillini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:164-176
5. Ginés A, Escorsell A, Ginés P, Salo J, Jimenez W, Inglada L, Navasa M, Claria J, Rimola A, Arroyo V (1993) Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105:229-236
6. Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL, Garcia-Plaza A, Leal J (1989) Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97:1304-1312
7. Arroyo V, Guevara M, Ginés P (2002) Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122:1658-1676
8. Wong F, Blendis L (2001) New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 34:1242-1251
9. Gonwa TA, Morris CA, Goldstein RM, Husbert BS, Klintmalm GB (1991) Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 91:428-430
10. Gonwa TA, Klintmalm GB, Jennings LS, Goldstein RM, Husberg B (1995) Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59:361-365
11. Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE (1973) Recovery from hepatorenal syndrome after orthotopic liver transplantation. N Engl J Med 289:1155-1159
12. Ortega R, Ginés P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941-948
13. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923-930
14. Duhamel C, Mauillon J, Berkelmans I, Bourienne A, Tranvouez JL (2000) Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 95:2984-2985
15. Gulberg V, Bilzer M, Gerbes AL (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30:870-875
16. Angeli P, Volpin R, Gerunda G, Craighero R, Romero P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffel-Faccioli A, Gatta A (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29:1690-1697
17. Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563-572
18. Cárdenas A, Ginés P, Rodés J (2003) Renal complications. In: Schiff ER, Sorrell MF, Maddrey WC (eds) Schiff's diseases of the liver. 9th ed. Lippincott Williams & Wilkins, Philadelphia, pp 497-509
19. Dagher L, Patch D, Marley R, Moore K, Burroughs A (2000) Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 14:515-521
20. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119:1637-1648
21. Wong F, Pantea L, Sniderman K (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40(1):55-64
22. Afessa B, Kublis PS (2000) Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol 95:484-489
23. Navasa M, Rodes J (1997) Management of ascites in the patient with portal hypertension with emphasis on spontaneous bacterial peritonitis. Semin Gastrointest Dis 8:200-209
24. Papper S (1983) The hepatorenal syndrome. In: Epstein M (ed) The kidney in liver disease. 2nd ed. Elsevier Biomedical, New York, pp 87-106